Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases

98

Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases

Tags:

Previous Article

ALS drug effectively treats Alzheimer’s disease

Inhibition of ceramide synthesis contributes to cardiometabolic diseases

Related Posts

Discovery of an allosteric binding site for anthraquinones at the human P2X4 receptor

Discovery of an allosteric binding site for anthraquino...

31

Human monoclonal antibodies targeting A35 protect from death caused by mpox

Human monoclonal antibodies targeting A35 protect from ...

48

RNA dysregulation in neurodegenerative diseases

RNA dysregulation in neurodegenerative diseases

107